

CURRICULUM VITAE - MICHAEL LARSEN

Present position

Professor of Clinical Ophthalmology, Glostrup Hospital and National Eye Clinic, University of Copenhagen.

Education and training

| | |
|---|------------|
| Specialist Authorisation, ophthalmology | Feb. 1996 |
| Doctor of Medical Science, University of Copenhagen | April 1993 |
| Medical Doctor, University of Copenhagen | Feb. 1985 |

Original papers

1. Larsen M, Krogsaa M, Warburg M, Sørensen SA, Lund-Andersen H: Carriers of X-linked Retinitis Pigmentosa. A Fluorophotometric Determination of the Permeability of the Blood-Retinal Barrier. *Ophthalmic Paediatrics and Genetics*. 7: 21-28, 1986
2. Larsen M, Fledelius H, Olsen W, Dalgaard P, Miyamoto K, Lund-Andersen H: Photometric Oculometry Using the Fluorotron Master. In: *Ocular Fluorophotometry*, pp. 33-37, eds. Brancato R and Coscas G, Kugler Publications, Amsterdam, 1987.
3. Larsen M, Dalgaard P, Lund-Andersen H: Differential Spectrofluorophotometry in the Human Vitreous Body. Noninvasive Assessment of the Visual System Technical Digest, (Optical Society of America), Washington, D.C. pp. 144-147, 1987.
4. Lund-Andersen H, Larsen M, Dalgaard P, Olsen W: Fluorescein and Fluorescein Glucuronide in the Vitreous Body of Diabetic Patients. *Graefe's Arch Clin Exp Ophthalmol* 225:173-176, 1987.
5. Larsen M, Steffen Loft, Eva Hommel, Lund-Andersen H: Fluorescein and Fluorescein Glucuronide in Plasma After Intravenous Injection of Fluorescein. *Acta Ophthalmol* 66: 427-432, 1988.
6. Kjer B, Larsen M, Dalgaard P, Bendtson I, Binder C, Lund-Andersen H: Lens Autofluorescence in Diabetes Compared with the Level of Glycosylated Hemoglobin A1c. *Acta Ophthalmologica*, 65 (1987) Suppl. 182, 100-102.
7. Ring K, Larsen M, Dalgaard P, Lund-Andersen H: Fluorophotometric Evaluation of Ocular Barriers and of the Vitreous Body in the Aphakic Eye. *Acta Ophthalmologica*, 65 (1987) Suppl. 182, 160-162.
8. Larsen M, Kjer B, Bendtson I, Dalgaard P, Lund-Andersen H: Lens Fluorescence in Relation to Metabolic Control of Insulin-Dependent Diabetes Mellitus. *Arch Ophthalmol* 107:59-62, 1989.
9. Larsen M, Johansson L: Time-Resolved Fluorescence Properties of Fluorescein and Fluorescein Monoglucuronide. *Exp Eye Res* 48:477-485, 1989.

10. Larsen M, Lund-Andersen H: In Vitro Models of Lens Fluorometry. Comparison With Lens Fluorometry In Vivo. in: Ocular Fluorometry and the Future. Proceedings of the IVth Symposium of the International Society of Ocular Fluorophotometry, eds.: Cunha-Vaz JG and Leite E, pp. 63-68, Kugler & Ghedini Publications, Amsterdam, 1989.
11. Lund-Andersen H, Larsen M, Larsen H-W, Dalgaard P, Hommel E, Parving H-H: Vitreous Fluorophotometry as a Possible Predictor of the Development of Diabetic Retinopathy: A Pilot Study. in: Ocular Fluorometry and the Future. Proceedings of the IVth Symposium of the International Society of Ocular Fluorophotometry, eds.: Cunha-Vaz JG and Leite E, pp. 165-167, Kugler & Ghedini Publications, Amsterdam, 1989.
12. Engler C, Larsen M, Bek T, Lund-Andersen H, Larsen S, Hilsted J, Worning H: Blood-Retinal Barrier Permeability in Diabetes Mellitus Secondary to Chronic Pancreatitis. in: Ocular Fluorometry and the Future. Proceedings of the IVth Symposium of the International Society of Ocular Fluorophotometry, eds.: Cunha-Vaz JG and Leite E, pp. 137-139, Kugler & Ghedini Publications, Amsterdam, 1989.
13. Bek T, Larsen M, Lund-Andersen H: Accurate Superimposition of Perimetry Data Onto Corresponding Retinal Locations. Preliminary Observations in Diabetic Retinopathy. *Exp Ophthalmol (Coimbra)* 14:57-58, 1988.
14. Larsen M, Lund-Andersen H: Fluorescein and Fluorescein Glucuronide in Vitreous: Fluorescence and Binding Properties in Vitro. *Acta Ophthalmol* 67:137-140, 1989.
15. Parving H-H, Larsen M, Hommel E, Lund-Andersen H: Effect of Antihypertensive Treatment on Blood-Retina Barrier Permeability To Fluorescein in Hypertensive Type 1 (Insulin-Dependent) Diabetic Patients with Background Retinopathy. *Diabetologia* 32:440-444, 1989.
16. Dalgaard P, Larsen M, Barker V: Fitting Models Given as Numerical Solutions to Systems of Differential Equations: A Case Study on Vitreous Fluorophotometry. Research Report 87/12, Statistical Research Unit, University of Copenhagen, Copenhagen 1987.
17. Kierkegaard C, Nørgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H: Effect of One Year Continuous Subcutaneous Infusion of a Somatostatin Analogue, Octreotide, on Early Retinopathy, Metabolic Control, and Thyroid Function in Type 1 (Insulin-Dependent) Diabetes Mellitus. *Acta Endocrinologica*, 122:766-772, 1990.

18. Dalgaard P, Larsen M: Fitting Numerical Solutions of Differential Equations to Experimental Data: A Case Study and Some General Remarks. *Biometrics* 46:1097-1109, 1990.
19. Larsen M, Hommel E, Parving H-H, Lund-Andersen H: Protective Effect of Captopril on the Blood-Retina Barrier in Normotensive Insulin-Dependent Diabetic Patients with Nephropathy and Background Retinopathy. *Graefe's Arch Clin Exp Ophthalmol* 228:505-509, 1990.
20. Larsen M, Dalgaard P, Lund-Andersen H: Differential Spectrofluorometry in the Human Vitreous: Blood-Retina Barrier Permeability of Fluorescein and Fluorescein Glucuronide. *Graefe's Arch Clin Exp Ophthalmol* 229:350-357, 1991.
21. Larsen M, Dalgaard P, Lund-Andersen H: Determination of Spatial Coordinates in Ocular Fluorometry. *Graefe's Arch Clin Exp Ophthalmol* 229:358-362, 1991.
22. Larsen M, Lund-Andersen H: Lens Fluorometry: Light Attenuation Effects and Estimation of Total Lens Transmittance. *Graefe's Arch Clin Exp Ophthalmol* 229:363-370, 1991.
23. Engler C, Parving H-H, Mathisen ER, Larsen M, Lund-Andersen H: Blood-Retina Barrier Permeability in Diabetes During Acute ACE-Inhibition. *Acta Ophthalmol* 69:581-585, 1991.
24. Storr-Paulsen A, Larsen M: Long-Term Results of Extracapsular Cataract Extraction with Posterior Chamber Lens Implantation: Sodium Hyaluronate 1% vs. Hydroxypropyl Methylcellulose 2%. *Acta Ophthalmol* 69:766-769, 1991.
25. Larsen M, Kjer B, Bendtson I, Dalgaard P, Lund-Andersen H: Lens Fluorescence in Relation to Nephropathy in Insulin-Dependent Diabetes Mellitus. *Graefe's Arch Clin Exp Ophthalmol* 230:6-10, 1992.
26. Engler CB, Sander B, Koefoed P, Larsen M, Vinding T, Lund-Andersen H: Interferon Alpha-2a Treatment of Patients with Subfoveal Neovascular Macular Degeneration. A Pilot Study. *Acta Ophthalmol* 71:27-31, 1993.
27. Larsen M: Ocular Fluorometry: Methodological Improvements and Clinical Studies with Special Reference to the Blood-Retina Barrier Permeability to Fluorescein and Fluorescein Glucuronide. Doctoral thesis. *Acta Ophthalmol* 71(suppl. 211):1-52, 1993.
28. Larsen M: Fluorometric assessment of equivalent healthy lens age for diabetics. *Invest Ophthalmol Vis Sci* (Letter to the Editor) 34:2607, 1993.

29. Larsen M: Determination of Blood-Retina Barrier Permeability. In 'Manual of Ocular Fluorometry', eds. Cunha-Vaz JG, Leite E, Ramos MC. Coimbra 1993. ISBN 972-95958-0-1.
30. Sander B, Larsen M, Engler C, Lund-Andersen H: Absence of Foveal Avascular Zone Demonstrated by Laser Scanning Fluorescein Angiography. *Acta Ophthalmol* 72:550-552, 1994.
31. Sander B, Larsen M, Engler C, Lund-Andersen H, Parving H-H: Early Changes in Diabetic Retinopathy: Capillary Loss and Blood-Retina Barrier Permeability in Relation to Metabolic Control. *Acta Ophthalmol* 72:553-559, 1994.
32. Engler CB, Sander B, Larsen M, Dalgaard P, Lund-Andersen H: Fluorescein Transport Across the Human Blood-Retina Barrier in the Direction Vitreous to Blood. *Acta Ophthalmol* 72:655-662, 1994.
33. Engler CB, Sander B, Larsen M, Koefoed P, Parving H-H, Lund-Andersen H: Probenecid Inhibition of the Outward Transport of Fluorescein Across the Human Blood-Retina Barrier. *Acta Ophthalmol* 72:663-667, 1994.
34. Sander B, Larsen M: Photochemical bleaching of fluorescent glycosylation products. *Int Ophthalmol* 18:195-198, 1995.
35. Theil PK, Hansen T, Larsen M, Pedersen O, Lund-Andersen H: Lens Fluorescence is Increased in Newly Diagnosed Patients with NIDDM. *Diabetologia* 39:1524-1527, 1996.
36. Schaik HJ van, Heintz B, Larsen M, Leite E, Rosas V, Schalnus R, Best JA van: Permeability of the blood-retinal barrier in healthy humans. *Graefe's Arch Clin Exp Ophthalmol* 235:639-646, 1997.
37. Larsen M, Engler CB, Haim M, Lund-Andersen H: Blood-Retina Barrier Permeability is Independent of Trace Substance Lipid Solubility in Healthy Eyes and in Retinitis Pigmentosa. *Int Ophthalmol* 21:229-234, 1998.
38. Christoffersen N, Sander B, Larsen M: Precipitation of hard exudate after resorption of intraretinal edema after treatment of retinal branch vein occlusion. *Am J Ophthalmol* 126:454-456, 1998.
39. Jensen OM, Larsen M: Objective Assessment of Photoreceptor Displacement and Metamorphopsia: A Study of Macular Holes. *Arch Ophthalmol* 116: 1303-1306, 1998.
40. Larsen M, Toft PB, Bernhardt P, Herning M: Bilateral Optic Neuritis in Acute Human Immunodeficiency Virus Infection. *Acta Ophthalmol Scand* 76:737-738, 1998.

41. Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H: The Effect of Azetazolamide on Passive and Active Transport of Fluorescein Across the Blood-Retina Barrier in Retinitis Pigmentosa complicated by macular edema. *Graefe's Arch Clin Exp Ophthalmol* 236:881-889, 1998.
42. Larsen M, Wieslander S: Effective Relief of Acute Orbital Compartment Syndrome by Lateral Cantholysis. *Acta Ophthalmol Scand* 77:232-233, 1999.
43. Wang M, Larsen M, Sander B, Lund-Andersen: Detection of shallow detachments in central serous chorioretinopathy. *Acta Ophthalmol Scand* 77:402-405, 1999.
44. Moldow B, Sander B, Larsen M, Lund-Andersen Henrik: Effects of acetazolamide on passive and active transport of fluorescein across the normal blood-retina barrier. *Invest Ophthal Vis Sci* 1999; 40(8):1770-5.
45. Pedersen L, Grunkin M, Ersbøll B, Madsen K, Larsen M, Christoffersen N, Skands U: Quantitative measurement of changes in retinal vessel diameter in ocular fundus images. *Pattern Recognition Letters* 21:1215-1223, 2001.
(http://www.elsevier.com/wps/find/journaldescription.cws_home/505619/description).
46. Tingsgaard LK, Sander B, Larsen M: Enhanced Visualisation of Acute Macular Neuroretinopathy by Spectral Imaging. *Acta Ophthalmol Scand* 1999;77(5):592-3.
47. Kessel L, Alsing A, Larsen M: Diabetic versus Non-Diabetic Pseudophakic Color Vision. *Br J Ophthalmol* 1999;83:1042-1045.
48. Christoffersen N, Larsen M: Pathophysiology and hemodynamics of branch retinal vein occlusion. *Ophthalmology* 106:2054-2062, 1999.
49. Haamann P, Kessel L, Larsen M: Monofocal Outer Retinitis Associated with Hand, Foot, and Mouth Disease Caused by Coxsackievirus. *Am J Ophthalmol* 129:552-553, 2000.
50. Sander B, Larsen M, Moldow B, Lund-Andersen H: Passive and active transport of fluorescein in diabetic macular edema. Introducing a simplified mathematical model of active transport. *Invest Ophthalmol Vis Sci* 2001;42:433-438.
50. Moldow B, Larsen M, Sander B, Lund-Andersen. Passive permeability and outward active transport of fluorescein across the blood-retinal barrier in early ARM. *Br J Ophthalmol* 2001;85(5):592-7.
51. Hougaard JLH, Wang M, Sander B, Larsen M: Effects of pseudophakic lens capsule opacification on optical coherence tomography of the macula. *Curr Eye Res* 2001;23:415-421.

52. Sander B, Larsen M, Engler C, Strøm C, Moldow B, Larsen N, Lund-Andersen H: Diabetic macular oedema: A comparison between vitreous fluorometry, angiography and retinopathy. *Br J Ophthalmol* 2002;86:316-320.
53. Strøm C, Sander B, Larsen N, Larsen M, Lund-Andersen H: Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. *Invest Ophthalmol Vis Sci* 2002;43:241-245.
54. Verteporfin Roundtable 2000 and 2001 Participants: Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators.; Verteporfin in photodynamic therapy (VIP) study group principal investigators: Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2002;22:6-18.
55. Wang M, Sander B, Larsen M: Retinal atrophy in idiopathic central serous chorioretinopathy. *Am J Ophthalmol* 133:787-793, 2002.
56. Kessel L, Hougaard JL, Sander B, Kyvik KO, Sørensen TIA, Larsen M: Lens ageing as an indicator of tissue damage associated with smoking and nonenzymatic glycation – a twin study. *Diabetologia* 45:1457-1462, 2002.
57. Kessel L, Kalinin S, Larsen M, Johansson LB-Å: Time-resolved and steady-state fluorescence spectroscopic studies of the human lens with comparison to Argpyrimidine, Pentosidine and 3-OH-kynurenine. *Photochemistry and Photobiology* 76:549-554, 2002.
58. Sander B, Larsen M, Engler C, Moldow B, Lund-Andersen H: Sander B, Larsen M, Engler C, Moldow B, Lund-Andersen H: Diabetic macular edema: The effect of photocoagulation on fluorescein transport across the blood-retina barrier. *Br J Ophthalmol*. 2002 (86): 1139-1142.
59. Larsen M, Godt J, Larsen N, Lund-Andersen H, Sjølie AK, Agardh E, Kalm H, Grunkin M, Owens DR: Automated detection of fundus photographic red lesions in diabetic retinopathy. *Invest Ophthalmol Vis Sci* 44(2):761-766, 2003.
60. Larsen N, Godt J, Grunkin M, Lund-Andersen H, Larsen M: Automated detection of diabetic retinopathy in a fundus photographic screening population. *Invest Ophthalmol Vis Sci* 44(2):767-771, 2003.
61. Taarnhøj NCBB, Kjeka O, Larsen M: Kinetics of retinal lipoprotein precipitation and elimination after closure of subretinal new vessels. *Invest Ophthalmol Vis Sci* 44(4):1680-1685, 2003.
62. Hougaard JL, Kessel L, Sørensen TIA, Kyvik KO, Larsen M: Evaluation of heredity as a determinant of retinal nerve fiber layer thickness as measured by optical coherence tomography. *Invest Ophthalmol Vis Sci* 44: 3011-3016, 2003.

63. Kessel L, Hougaard JL, Sander B, Kyvik KO, Sørensen TIA, Larsen M: Corneal fluorescence in relation to genetic and environmental factors: a twin study. *Acta Ophthalmologica* 81:508-513, 2003.
64. Kessel L, Glümer C, Larsen M: Estimation of prediagnostic duration of type 2 diabetes mellitus by lens autofluorometry. *Proc of SPIE* 5141:289-297, 2003.
65. Kessel L, Hougaard JL, Mortensen C, Jørgensen T, Lund-Andersen H, Larsen M: Visual acuity and refractive errors in a suburban Danish population: Inter99 Eye Study. *Acta Ophthalmologica* 82:19-24, 2004.
66. Kessel L, Sander B, Dalgaard P, Larsen M: Lens fluorescence and metabolic control in type 1 diabetic patients – a 14 year follow-up study. *Br J Ophthalmol* 88:1169-1172, 2004.
67. Klemp K, Larsen M, Sander B, Vaag A, Brockhoff PB, Lund-Andersen H: Effect of short-term hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. *Invest Ophthalmol Vis Sci* 45:3812-3819, 2004.
68. Christoffersen N, Larsen M: Unilateral Diabetic Macular Edema Secondary to Low-Grade Compression of the Central Retinal Vein. *Acta Ophthalmol* 82:591-595, 2004.
69. Sander B, Larsen M, Thrane L, Hougaard JL, Jorgensen TM: Enhanced optical coherence tomography imaging by multiple scan averaging. *Br J Ophthalmol* 89:207-212, 2005.
70. Hansen AB, Hartvig NV, Jensen MS, Borch-Johnsen K, Lund-Andersen H, Larsen M: Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis. *Acta Ophthalmologica* 82:666-672; 2004.
71. Hansen AB, Sander B, Larsen M, Kleener J, Borch-Johnsen K, Klein R, Lund-Andersen H: Screening for diabetic retinopathy using a digital non-mydriatic camera compared with standard 35-mm stereo colour transparencies. *Acta Ophthalmologica* 82:656-665; 2004.
72. Gragoudas ES, Adamis AP, Cunningham E, Feinsod M, Guyer DR, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for Neovascular Age-Related Macular Degeneration. *New England Journal of Medicine* 351:2805-2816, 2004.
73. Larsen M, Colmorn LB, Bønnelycke M, Kaaja R, Immonen I, Sander B, Loukovaara S: Retinal artery and vein diameters during pregnancy in diabetic women. *Invest Ophthalmol Vis Sci* 46:709-713;2005.
74. Krøyer K, Jensen OM, Larsen M: Objective Signs of Photoreceptor Displacement by Binocular Correspondence Perimetry: A Study of Epiretinal Membranes. *Invest Ophthalmol Vis Sci* 46:1017-1022; 2005.

75. Kessel L, Kalinin S, Soroka V, Larsen M, Johansson LB-Å: Photochemical destruction of chromophores in the human lens by UVA. *Acta Ophthalmologica* 83:221-227, 2005.
76. Larsen M, Wang M, Sander B: Overnight variation in retinal thickness in diabetic macular edema. *Invest Ophthalmol Vis Sci* 46:2313-2316, 2005.
77. Larsen M: Unilateral macular oedema secondary to retinal venous congestion without occlusion in patients with diabetes mellitus. *Acta Ophthalmologica* 83:428-435, 2005.
78. Wang M, Sander B, la Cour M, Larsen M: Clinical characteristics of subretinal deposits in idiopathic central serous chorioretinopathy. *Acta Ophthalmologica* 83:691-696, 2005.
79. Klemp K, Sander B, Lund-Andersen H, Larsen M: The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. *Invest Ophthalmol Vis Sci* 46:2620-2626, 2005.
80. Taarnhøj NC, Munch IC, Kyvik K, Sander B, Kessel L, Sørensen TIA, Hougaard JL, Larsen M: Heritability of Cilioretinal Arteries - A Twin Study. *Invest Ophthalmol Vis Sci* 46:3850-3854, 2005.
81. Larsen C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M: Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. *Invest Ophthalmol Vis Sci* 46:3855-3888, 2005.
82. Sørensen TL, Haamann P, Villumsen J, Larsen M: Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. *Acta Ophthalmol*. 2005 Feb;83(1):67-70.
83. The VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N) clinical trial group: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina* 25:815-827, 2005.
84. Larsen M, Pedersen R, Taarnhoj NCBB, Spits Y, Munch IC, Leroy BP, Klemp K: Retinal vessel dilation following repletion of vitamin A deficiency. *Experimental Eye Research* 82:349-50, 2006. Epub 2005 Dec 20.
85. Soliman WM, Haamann P, Larsen M: Spontaneous exudation followed by complete remission in racemose hemangioma. *Acta Ophthalmologica* 84:429-431, 2006.
86. Soliman W, Lund-Andersen H, Larsen M: Early resolution of subretinal hemorrhage and fluid after intravitreal bevacizumab in a case of aggressive peripapillary subretinal neovascularization. *Acta Ophthalmologica* 2006, E-pub June 22.
87. D'Amico DJ; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group: Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration Two-Year Safety Results of the Two Prospective, Multicenter, Controlled Clinical Trials. *Ophthalmology* 2006; 113:992-1001.

88. Kessel L, Jørgensen T, Glümer C, Larsen M: Early lens aging is accelerated in subjects with a high risk of ischemic heart disease: an epidemiologic study. *BMC Ophthalmology* 6:16, 2006.
89. Taarnhøj NCBB, Sander B, Kyvik K, Kessel L, Hougaard JL, Sørensen TIA, Larsen M: Heritability of retinal vessel diameters and blood pressure: a twin study. *Investigative Ophthalmology and Visual Science* 47:3539-3544, 2006.
90. Gardner TW, Sander B, Larsen M, Kunselman A, Have TT, Lund-Andersen H, Reimers J, Hubbard L, Blankenship GW, Quillen DA, Brod RD, Wilmarth MH, Hansen HP, Parving H-H, Davis MD: An Extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) System for Grading of Diabetic Macular Edema in the Astemizole Retinopathy Trial. *Curr Eye Res* 31:535 - 547, 2006.
91. Tsang SH, Woodruff ML, Lin J, Mahajan V, Yamashita CK, Pedersen R, Lee W-H, Lin C-S, Jensen H, Goff SP, Rosenberg T, Larsen M, Farber DB, Nusinowitz S: Transgenic Mice Carrying An Allele of A Human Congenital Stationary Night Blindness (CSNB) Gene. *Human Mutation* 2007, 28:243-254.
92. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group: Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2006;113:1508–1521.
93. Theil PK, Kessel L, Hansen T, Lund-Andersen, Pedersen OB, Larsen M: Lens fluorescence in type 2 diabetes detected by population screening. *Curr Eye Res* 31:733-738, 2006.
94. Soliman W, Wegener M, Sander B, Larsen M, Milea D: Optical coherence tomography of astrocytic hamartomas in tuberous sclerosis. *Acta Ophthalmol*. 2007 Jun;85(4):454-455.
95. Munch IC, Kessel K, Taarnhøj N, Sander B, Hougaard JL, Sørensen TIA, Kyvik KO, Larsen M: Heredity of small hard drusen in twins aged 21-46 years. *Invest Ophthalmol Vis Sci* 2007, 48:833-838.
96. Vinten M, Larsen M, Lund-Andersen H, Birgit Sander B, la Cour M: Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessels diameters in diabetic macular edema. *Acta Ophthalmologica* 2007, 85:21-26.
97. Soliman W, Zibrandtsen N, Jørgensen TM, Sander B, Alsbirk PH, Larsen M: Sequels of Purtscher's retinopathy imaged by enhanced optical coherence tomography. *Acta Ophthalmol* 2007 85:450-453.
98. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. *Acta Ophthalmol* 2007;85:526-533.

99. Larsen M, Gondolf T, Larsen N, Jensen MS, Godt J, Hartvig NV, Lund-Andersen H: Safety of detecting treatment-requiring diabetic retinopathy and utility of bright lesion detection. *Current Eye Research* 2007, 32:331-336.
100. Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M: Mortality in patients with branch retinal vein occlusion. *Ophthalmology* 2007, 114:1186-1189.
101. Klemp K, Lund-Andersen H, Sander B, Larsen M. The effect of acute hypoxia and hyperoxia on the slow multifocal electroretinogram in healthy subjects. *Invest Ophthalmol Vis Sci* 2007;48:3405-3412.
102. Sander B, Thornit DN, Colmorn L, Strom C, Girach A, Hubbard LD, Lund-Andersen H, Larsen M: Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. *Invest Ophthalmol Vis Sci*. 2007;48:3983-3987.
103. Krøyer K, Cour M la, Larsen M: Dissociation of Rod and Cone Sensitivity by Acute Localized Retinal Pigment Epithelium Loss. *Acta Ophthalmol*. 86:338-340, 2008.
104. Soliman W, Sander B, Hasler PW, Larsen M: Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. *Acta Ophthalmol* 86:34-39, 2008.
105. Haamann P, Godt J, Andersen N, Langagergaard U, Børme KK, Krogsager JF, Gregersen P, Sørensen TL, Kiilgaard JF, Bek T, Edmund C, Larsen M: Patient's delay and physician's delay in neovascular age-related macular degeneration. *Submitted for publication*.
106. Photodynamic therapy in occult-only lesions (POOL) Study Group: Verteporfin therapy in occult with no classic CNV due to AMD: results of the photodynamic therapy in occult-only lesions (POOL) study. *E-pub 2008, Eye*.
107. Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS, Larsen M. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. *Acta Ophthalmol*. 2007 Nov 17. [Epub ahead of print].
108. Soliman W, Sander B, Soliman KA, Yehya S, Rahman MS, Larsen M. The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema. *Acta Ophthalmol*. 2007 Nov 13. [Epub ahead of print].
109. Krøyer K, Christensen U, Larsen M, la Cour M: Quantification of Metamorphopsia in Patients with Macular Hole. *Invest Ophthalmol Vis Sci*. April 30, 2008 doi:10.1167/iovs.07-1452
110. Taarnhøj NC, Munch IC, Sander B, Kessel L, Hougaard JL, Kyvik K, Sørensen TI, Larsen M: Straight versus tortuous retinal arteries in relation to blood pressure and genetics. *Br J Ophthalmol* 92:1055-60, 2008.

111. Zibrandtsen N, Munch IC, Sander B, Larsen M: Retinal atrophy in acute zonal occult outer retinopathy. *Acta ophthalmologica, E-pub 2008*.
112. Sander B, Hamann P, Larsen M: A 5-year follow-up of photocoagulation in diabetic macular edema: the prognostic value of vascular leakage for visual loss. *Graefes Arch Clin Exp Ophthalmol.* 2008 Jul 26. [Epub ahead of print]
113. Kofoed P, Milea D, Larsen M: Transient monocular blindness precipitated by sexual intercourse. *Br J Ophthalmol.* 2008 Jul 25. [Epub ahead of print]
<http://bjo.bmjjournals.org/cgi/pmidlookup?view=long&pmid=18658172>
114. Vinten M, la Cour M, Lund-Andersen H, Larsen M: Effect of acute postural variation on diabetic macular edema. *Accepted for publication, Acta Ophthalmologica.*
115. Kofoed PK, Sander B, Zubieta-Calleja G, Larsen M: Effect of high to low altitude adaptation on retinal vessel diameters. *In preparation.*
116. Kofoed PK, Sander B, Zubieta-Calleja G, Klemp K, Larsen M: Effect of high to low altitude adaptation on the multifocal electroretinogram. *In preparation.*

Reviews

117. la Cour M, Larsen M, Haamann P, Vinding T: Aldersrelateret maculadegeneration [Age related macular degeneration. A widespread disease]. *Ugeskrift for Læger*, 163:6396-6400, 2001.
118. Haamann P, Larsen M, Juhl HH, Svenning AR: Fotodynamisk behandling af karnydkællse bag øjens nethinde – en MTV-rapport. Sundhedsstyrelsen. Medicinsk Teknologivurdering – puljeprojekter 2002; 2(3). [Photodynamic therapy of subretinal neovascularization – a medical technology assessment report]. Danish Health Board, Copenhagen, 2002.
<http://www.mtv-instituttet.dk/publikationer/docs/Fotodynamiskbehand/148545.pdf> eller
<http://www.cemtv.dk>. ISBN elektronisk udgave: 87-91232-73-2.
119. Klitgaard TLS, Haamann P, Villumsen J, Larsen M: Intravitreal triamcinolonbehandling [Intravitreal triamcinolone treatment]. *Ugeskr Laeger* 167:1729-1731, 2005.
120. Munch IC, Larsen M: Iskæmisk øjensyndrom [The ocular ischemic syndrome]. *Ugeskr Laeger* 167:3269-3273, 2005.
121. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA, Korobelnik JF, Larsen M, Mones J, Pauleikhoff D, Pournaras CJ, Staurenghi G, Virgili G, Wolf S: Evolving European guidance on the medical management of neovascular age related macular degeneration. *Br J Ophthalmol* 90:1188-96, 2006.

122. Wang M, Munch IC, Hasler P, Prunte C, Larsen M: Review of current issues in central serous chorioretinopathy. *Acta Ophthalmol* 2007 Jul 28; [Epub ahead of print] .
123. Kessel L, Nymand J, Harbst M, van der Poel M, Eskildsen L, Larsen M. Femtosecond laser-induced cavitations in the lens of the human eye. Therapeutic Laser Applications and Laser-Tissue Interactions III. Progress in Biomedical Optics and Imaging. Vol 8 (45). 2007.
124. Bloch SB, Larsen M, Haamann P, Cour M la: Ny behandling af aldersrelateret maculadegeneration. Ugeskr Læger, 170:1048, 2008.
125. Bloch SB, Hansen MMO, Haamann P, Larsen M: Central serøs chorioretinopati. Ugeskr Læger 170:2015-2018, 2008.